228 related articles for article (PubMed ID: 24968029)
1. Macrophage depletion by free bisphosphonates and zoledronate-loaded red blood cells.
Sabatino R; Antonelli A; Battistelli S; Schwendener R; Magnani M; Rossi L
PLoS One; 2014; 9(6):e101260. PubMed ID: 24968029
[TBL] [Abstract][Full Text] [Related]
2. Macrophage depletion induced by clodronate-loaded erythrocytes.
Rossi L; Serafini S; Antonelli A; Pierigé F; Carnevali A; Battistelli V; Malatesta M; Balestra E; Caliò R; Perno CF; Magnani M
J Drug Target; 2005 Feb; 13(2):99-111. PubMed ID: 15823961
[TBL] [Abstract][Full Text] [Related]
3. Preclinical evaluation of an innovative anti-TAM approach based on zoledronate-loaded erythrocytes.
Sabatino R; Battistelli S; Magnani M; Rossi L
Drug Deliv Transl Res; 2018 Oct; 8(5):1355-1364. PubMed ID: 30014237
[TBL] [Abstract][Full Text] [Related]
4. Zoledronate attenuates angiotensin II-induced abdominal aortic aneurysm through inactivation of Rho/ROCK-dependent JNK and NF-κB pathway.
Tsai SH; Huang PH; Peng YJ; Chang WC; Tsai HY; Leu HB; Chen JW; Lin SJ
Cardiovasc Res; 2013 Dec; 100(3):501-10. PubMed ID: 24225494
[TBL] [Abstract][Full Text] [Related]
5. Zoledronate sensitizes endothelial cells to tumor necrosis factor-induced programmed cell death: evidence for the suppression of sustained activation of focal adhesion kinase and protein kinase B/Akt.
Bezzi M; Hasmim M; Bieler G; Dormond O; Rüegg C
J Biol Chem; 2003 Oct; 278(44):43603-14. PubMed ID: 12933798
[TBL] [Abstract][Full Text] [Related]
6. Liposome encapsulated zoledronate favours M1-like behaviour in murine macrophages cultured with soluble factors from breast cancer cells.
Sousa S; Auriola S; Mönkkönen J; Määttä J
BMC Cancer; 2015 Jan; 15():4. PubMed ID: 25588705
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo investigation of bisphosphonate-loaded hydroxyapatite particles for peri-implant bone augmentation.
Kettenberger U; Luginbuehl V; Procter P; Pioletti DP
J Tissue Eng Regen Med; 2017 Jul; 11(7):1974-1985. PubMed ID: 26549303
[TBL] [Abstract][Full Text] [Related]
8. Growth inhibition of macrophage-like and other cell types by liposome-encapsulated, calcium-bound, and free bisphosphonates in vitro.
Mönkkönen J; Taskinen M; Auriola SO; Urtti A
J Drug Target; 1994; 2(4):299-308. PubMed ID: 7858955
[TBL] [Abstract][Full Text] [Related]
9. Liposome-encapsulated zoledronate increases inflammatory macrophage population in TNBC tumours.
Petruk N; Sousa S; Croset M; Polari L; Zlatev H; Selander K; Mönkkönen J; Clézardin P; Määttä J
Eur J Pharm Sci; 2023 Nov; 190():106571. PubMed ID: 37652236
[TBL] [Abstract][Full Text] [Related]
10. Zoledronate and pamidronate depress neutrophil functions and survival in mice.
Kuiper JW; Forster C; Sun C; Peel S; Glogauer M
Br J Pharmacol; 2012 Jan; 165(2):532-9. PubMed ID: 21745192
[TBL] [Abstract][Full Text] [Related]
11. Reduced expression of CD47 during murine red blood cell (RBC) senescence and its role in RBC clearance from the circulation.
Khandelwal S; van Rooijen N; Saxena RK
Transfusion; 2007 Sep; 47(9):1725-32. PubMed ID: 17725740
[TBL] [Abstract][Full Text] [Related]
12. In vitro effects of bisphosphonates on chemotaxis, phagocytosis, and oxidative burst of neutrophil granulocytes.
Hagelauer N; Pabst AM; Ziebart T; Ulbrich H; Walter C
Clin Oral Investig; 2015 Jan; 19(1):139-48. PubMed ID: 24668343
[TBL] [Abstract][Full Text] [Related]
13. Mechanical loading influences the effects of bisphosphonates on human periodontal ligament fibroblasts.
Jacobs C; Walter C; Ziebart T; Dirks I; Schramm S; Grimm S; Krieger E; Wehrbein H
Clin Oral Investig; 2015 Apr; 19(3):699-708. PubMed ID: 25055746
[TBL] [Abstract][Full Text] [Related]
14. Hypotonically loaded rat erythrocytes deliver encapsulated substances into peritoneal macrophages.
Alvarez FJ; Jordán JA; Herráez A; Díez JC; Tejedor MC
J Biochem; 1998 Feb; 123(2):233-9. PubMed ID: 9538197
[TBL] [Abstract][Full Text] [Related]
15. Controlled release of bisphosphonate from a calcium phosphate biomaterial inhibits osteoclastic resorption in vitro.
Faucheux C; Verron E; Soueidan A; Josse S; Arshad MD; Janvier P; Pilet P; Bouler JM; Bujoli B; Guicheux J
J Biomed Mater Res A; 2009 Apr; 89(1):46-56. PubMed ID: 18404716
[TBL] [Abstract][Full Text] [Related]
16. Zoledronate but not denosumab suppresses macrophagic differentiation of THP-1 cells. An aetiologic model of bisphosphonate-related osteonecrosis of the jaw (BRONJ).
Hoefert S; Hoefert CS; Albert M; Munz A; Grimm M; Northoff H; Reinert S; Alexander D
Clin Oral Investig; 2015 Jul; 19(6):1307-18. PubMed ID: 25411080
[TBL] [Abstract][Full Text] [Related]
17. In vitro toxicity of bisphosphonates on human neuroblastoma cell lines.
Vorotnjak M; Boos J; Lanvers-Kaminsky C
Anticancer Drugs; 2004 Sep; 15(8):795-802. PubMed ID: 15494642
[TBL] [Abstract][Full Text] [Related]
18. Zoledronate, ibandronate and clodronate enhance osteoblast differentiation in a dose dependent manner--a quantitative in vitro gene expression analysis of Dlx5, Runx2, OCN, MSX1 and MSX2.
Koch FP; Merkel C; Al-Nawas B; Smeets R; Ziebart T; Walter C; Wagner W
J Craniomaxillofac Surg; 2011 Dec; 39(8):562-9. PubMed ID: 21030265
[TBL] [Abstract][Full Text] [Related]
19. Bisphosphonates induce breast cancer cell death in vitro.
Fromigue O; Lagneaux L; Body JJ
J Bone Miner Res; 2000 Nov; 15(11):2211-21. PubMed ID: 11092402
[TBL] [Abstract][Full Text] [Related]
20. Effects of clodronate and pamidronate on splenic and hepatic phagocytic cells of mice.
Mönkkönen J; van Rooijen N; Ylitalo P
Pharmacol Toxicol; 1991 Apr; 68(4):284-6. PubMed ID: 1830965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
